CheckMate 77T: Nivolumab Maintains Quality of Life and Reduces Symptom Deterioration in Resectable NSCLC

1. The CheckMate 77T trial focused on perioperative nivolumab in NSCLC. 2. Nivolumab showed no compromise to HRQoL in patients. 3. HRQoL was measured through NSCLC-SAQ and EQ-5D-3L VAS. 4. Over 90% PRO completion rates were reported. 5. Nivolumab reduced HRQoL deterioration risk in stage III N2 patients. 6. Quality of life benefits extend to single lobectomy or complete resection. 7. The study reinforces nivolumab’s role in enhancing patient well-being post-surgery.